UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Index Medicus | Abridged Index Medicus | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 04/2015, Volume 91, pp. 91 - 102
Dyskeratosis congenita | GSE24.2 peptide | Cell-penetrating peptides | Biodegradable nanoparticles | Polycations | Telomerase reactivation | Dyskeratosis congenital | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Recombinant Proteins - therapeutic use | Dyskeratosis Congenita - drug therapy | Nanoparticles - chemistry | Biocompatible Materials - chemistry | Humans | Enzyme Reactivators - administration & dosage | Polyethylene Glycols - chemistry | Telomerase - deficiency | Biological Transport | Drug Compounding | Telomerase - metabolism | Peptide Fragments - genetics | Cell Survival - drug effects | Lactic Acid - chemistry | Polyamines - chemistry | Enzyme Reactivators - chemistry | Recombinant Proteins - chemistry | Nuclear Proteins - chemistry | Peptide Fragments - chemistry | Delayed-Action Preparations - adverse effects | Telomerase - chemistry | Delayed-Action Preparations - therapeutic use | Drug Liberation | Lactic Acid - adverse effects | Polyglactin 910 - adverse effects | Mice | Peptide Fragments - adverse effects | Biocompatible Materials - adverse effects | Drug Delivery Systems - adverse effects | Polyamines - adverse effects | Polyglycolic Acid - adverse effects | Polyethylene Glycols - adverse effects | Delayed-Action Preparations - chemistry | Nanoparticles - adverse effects | Recombinant Proteins - adverse effects | Cell Cycle Proteins - administration & dosage | Delayed-Action Preparations - administration & dosage | Cell Cycle Proteins - chemistry | Nuclear Proteins - administration & dosage | Cell-Penetrating Peptides - adverse effects | Chemical Phenomena | Cell Cycle Proteins - genetics | Polyglactin 910 - chemistry | Protein Stability | Nuclear Proteins - genetics | Cell-Penetrating Peptides - chemistry | Cell Line | Cell Cycle Proteins - adverse effects | Drug Stability | Peptide Fragments - administration & dosage | Cells, Cultured | Nuclear Proteins - adverse effects | Recombinant Proteins - administration & dosage | Enzyme Reactivators - therapeutic use | Animals | Enzyme Reactivators - adverse effects | Polyglycolic Acid - chemistry | Peptides | Telomerase | Index Medicus
Journal Article
Nature reviews. Neurology, ISSN 1759-4758, 08/2012, Volume 8, Issue 8, pp. 465 - 469
Antibodies - metabolism | Humans | Alzheimer Disease - therapy | Amyloid beta-Peptides - immunology | Antibodies - adverse effects | Clinical Trials as Topic | Alzheimer Disease - immunology | Immunotherapy - adverse effects | Care and treatment | Immunotherapy | Amyloid beta-protein | Physiological aspects | Research | Alzheimer's disease | Health aspects | Index Medicus
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 07/2011, Volume 121, Issue 7, pp. 2693 - 2708
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Tumor Necrosis Factor-alpha - metabolism | Nitric Oxide - biosynthesis | Coronary Artery Disease - metabolism | Humans | Middle Aged | Lipoproteins, HDL - metabolism | Male | NF-kappa B - metabolism | Aryldialkylphosphatase - metabolism | Animals | Coronary Artery Disease - physiopathology | Endothelium, Vascular - metabolism | Adult | Female | Aged | Mice | Nitric Oxide Synthase Type III - metabolism | Proto-Oncogene Proteins c-akt - metabolism | Vascular Cell Adhesion Molecule-1 - metabolism | Prevention | Enzymes | Care and treatment | High density lipoproteins | Physiological aspects | Research | Coronary heart disease | Endothelium | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
Diabetes. Impaired glucose tolerance | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2015, Volume 313, Issue 13, pp. 1336 - 1346
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recombinant Proteins - therapeutic use | Antithrombins - therapeutic use | Humans | Middle Aged | Heparin - therapeutic use | Male | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tyrosine - analogs & derivatives | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Myocardial Infarction - drug therapy | Tyrosine - therapeutic use | Antithrombins - adverse effects | Fibrinolytic Agents - therapeutic use | Hirudins - adverse effects | Female | Tyrosine - adverse effects | Aged | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Percutaneous Coronary Intervention | Care and treatment | Usage | Angiography | Patient outcomes | Clinical trials | Bivalirudin | Dosage and administration | Heart attack | Medical research | Side effects | Inhibitor drugs | Heart attacks | Index Medicus | Abridged Index Medicus
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2011, Volume 141, Issue 1, pp. 150 - 156
Gastroenterology and Hepatology | Side Effect | Tumor | Pancreas | Toxicity | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Receptors, Glucagon - agonists | Triazoles - adverse effects | United States - epidemiology | Pancreatic Neoplasms - epidemiology | Risk Assessment | Adverse Drug Reaction Reporting Systems | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Pancreatitis - epidemiology | Venoms - adverse effects | Humans | Risk Factors | Thyroid Neoplasms - epidemiology | Pancreatitis - chemically induced | Diabetes Mellitus, Type 2 - epidemiology | Thyroid Neoplasms - chemically induced | Glucagon-Like Peptide-1 Receptor | Pyrazines - adverse effects | Pancreatic Neoplasms - chemically induced | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Odds Ratio | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | United States Food and Drug Administration | Type 2 diabetes | Care and treatment | Thyroid cancer | Peptides | Pancreatitis | Cancer | Index Medicus | Abridged Index Medicus
Journal Article